TPW
NBIX icon

Talon Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Talon Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$631K Buy
+4,789
New +$635K 0.08% 132
2025
Q2 		$30.4K Buy
+242
New +$27.8K ﹤0.01% 223
2025
Q1 		– Sell
-2
Closed -$273 – 256
2024
Q4 		$273 Sell
2
-77
-97% -$9.52K ﹤0.01% 289
2024
Q3 		$9.1K Buy
+79
New +$10.8K ﹤0.01% 187

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Talon Private Wealth's NBIX Position: Q1 2026 in Review

Talon Private Wealth opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 4,789 shares worth $631K. The stake represents 0.08% of the portfolio and ranks #132 among its holdings. This is a return to the name: Talon Private Wealth previously reported a position in NBIX as recently as Q2 2025.

Talon Private Wealth first reported a position in NBIX in Q3 2024 and has held it in 4 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Talon Private Wealth held 4,789 shares of Neurocrine Biosciences worth $631K as of Q1 2026.
  • Neurocrine Biosciences was a new Talon Private Wealth position in Q1 2026.
  • Neurocrine Biosciences made up 0.08% of Talon Private Wealth's portfolio in Q1 2026, its #132 holding.
  • Talon Private Wealth first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 4 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Talon Private Wealth's 13F filing for Q1 2026, filed 18 May 2026.